Looking at Seelos Therapeutics (NASDAQ:SEEL) and Cyclerion Therapeutics (NASDAQ:CYCN)

Cyclerion Therapeutics ( NASDAQ:CYCN – Get Free Report ) and Seelos Therapeutics ( NASDAQ:SEEL – Get Free Report ) are both small-cap medical companies, but which is the better investment? We’ll compare the two companies based on valuation strength, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Rating and Earnings

This table compares the revenue, earnings per share (EPS) and valuation of Cyclerion Therapeutics and Seelos Therapeutics.

Cyclerion Therapeutics has higher revenue, but lower revenue than Seelos Therapeutics.

Risk and volatility

Cyclerion Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 1.89, indicating that its share price is it is 89% more volatile than the S&P 500.

Insider and institutional ownership

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 23.4% of Seelos Therapeutics shares are held by institutional investors. 13.1% of Cyclerion Therapeutics shares are held by insiders. Comparatively, 5.4% of Seelos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that big money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

return

This table compares Cyclerion Therapeutics and Seelos Therapeutics’ net margins, return on equity and return on assets.

Analyst ratings

This is a breakdown of recent recommendations and price targets for Cyclerion Therapeutics and Seelos Therapeutics, provided by MarketBeat.com.

Seelos Therapeutics has a consensus target price of $360.00, suggesting a potential upside of 104,036.53%. Given Seelos Therapeutics’ higher probable upside, analysts plainly believe Seelos Therapeutics is more favorable than Cyclerion Therapeutics.

Summary

Cyclerion Therapeutics beats Seelos Therapeutics in 7 of the 11 factors compared between the two stocks.

About Cyclerion Therapeutics

(Get a free report)

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, is in development and is in Phase 2 clinical trials to be licensed for cardiovascular disease; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

About Seelos Therapeutics

(Get a free report)

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing medicines for the treatment of central nervous system, respiratory system and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson’s disease (PD). Its preclinical programs include SLS-007, a peptide inhibitor for the treatment of PD patients; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

Get daily news and reviews for Cyclerion Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cyclerion Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.